

# Ventilator Associated Pneumonia Therapeutic Pipeline Market Review, H2 2016

*Ventilator Associated Pneumonia Treatment Pipeline Review H2 2016*

PUNE, INDIA, October 21, 2016 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for [Ventilator Associated Pneumonia](#) (VAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/619299-ventilator-associated-pneumonia-vap-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

## Scope

- The report provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP)
- The report reviews pipeline therapeutics for Ventilator Associated Pneumonia (VAP) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other



**WISE GUY**  
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

## developmental activities

- The report reviews key players involved Ventilator Associated Pneumonia (VAP) therapeutics and enlists all their major and minor projects
- The report assesses Ventilator Associated Pneumonia (VAP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Ventilator Associated Pneumonia (VAP)

## Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ventilator Associated Pneumonia (VAP)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

## Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Ventilator Associated Pneumonia (VAP) Overview 9

Therapeutics Development 10

Pipeline Products for Ventilator Associated Pneumonia (VAP) - Overview 10

Pipeline Products for Ventilator Associated Pneumonia (VAP) - Comparative Analysis 11

Ventilator Associated Pneumonia (VAP) - Therapeutics under Development by Companies 12

Ventilator Associated Pneumonia (VAP) - Therapeutics under Investigation by

Universities/Institutes 14

Ventilator Associated Pneumonia (VAP) - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Ventilator Associated Pneumonia (VAP) - Products under Development by Companies 19

Ventilator Associated Pneumonia (VAP) - Products under Investigation by Universities/Institutes 20

Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development 21

Achaogen Inc. 21

Adenium Biotech ApS 22

Aridis Pharmaceuticals LLC 23

AstraZeneca Plc 24

Bayer AG 25

Cardeas Pharma Corp. 26

MedImmune, LLC 27

Meiji Seika Pharma Co., Ltd. 28  
Merck & Co., Inc. 29  
Motif Bio Plc 30  
Nabriva Therapeutics AG 31  
Savara Inc. 32  
Shionogi & Co., Ltd. 33  
Tetraphase Pharmaceuticals Inc. 34  
Zavante Therapeutics, Inc. 35  
Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment 36  
Assessment by Monotherapy Products 36  
Assessment by Combination Products 37  
Assessment by Target 38  
Assessment by Mechanism of Action 41  
Assessment by Route of Administration 44

Access Report @ <https://www.wiseguyreports.com/reports/619299-ventilator-associated-pneumonia-vap-pipeline-review-h2-2016>

Get in touch:

LinkedIn: [www.linkedin.com/company/4828928](http://www.linkedin.com/company/4828928)

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.